Lonza Accelerates the Future of Pharma QC with Acquisition of Redberry and Its Breakthrough Red One™ Rapid Microbiology Platform

  Lonza to acquire Redberry SAS, an innovative company specializing in rapid microbiology testing solutions Acquisition to include Red One&trade...

October 29, 2025 | Wednesday | News
Gelteq Initiates Preclinical Trial with Monash University to Advance Oral Delivery of Oily and Poorly Soluble Drugs

Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...

October 24, 2025 | Friday | News
Cytiva Achieves ISCC PLUS Certification for Biobased Resins in Whatman Filtration Devices

Labs will soon have access to filtration products made with ISCC PLUS-certified biobased resins Certified materials enable labs to choose more sustainab...

October 24, 2025 | Friday | News
Cumberland Pharmaceuticals Invests $4 Million for 30% Stake and Joint Control in RedHill’s Talicia Business

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill'...

October 21, 2025 | Tuesday | News
Adcytherix Raises €105 Million Series A to Advance Next-Generation Antibody–Drug Conjugates with Novel Payloads

Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led b...

October 20, 2025 | Monday | News
Rani Therapeutics Enters $1 Billion Collaboration with Chugai for Oral Biologics Development

Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $10...

October 20, 2025 | Monday | News
Agios Pharmaceuticals Receives CHMP Positive Opinion for PYRUKYND® in Treating Alpha- and Beta-Thalassemia

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rar...

October 20, 2025 | Monday | News
Azurity Pharmaceuticals Receives FDA Approval for Ferabright™, the First Iron-Based MRI Contrast Agent for Brain Tumour Imaging

Azurity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the first and...

October 20, 2025 | Monday | News
China NMPA Accepts Belite Bio’s NDA for Tinlarebant with Priority Review Based on Phase 3 DRAGON Interim Data

NMPA’s response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025  Belite Bio, Inc. (NASDAQ...

October 16, 2025 | Thursday | News
SCYNEXIS to Receive $22 Million from GSK as Phase 3 MARIO Study on Invasive Candidiasis Is Terminated

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis...

October 16, 2025 | Thursday | Regulatory
Excellergy Launches with $70M Series A to Redefine Allergy Treatment with First-in-Class Trifunctional ECRIs

-Redefining Allergy Treatment with New Class of Trifunctional ECRIs designed to deliver powerful efficacy, rapid relief and complete control of alle...

October 14, 2025 | Tuesday | News
Nasus Pharma Partners with Aptar to Advance Intranasal Epinephrine NS002 Toward Commercialization

Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the developm...

October 13, 2025 | Monday | News
Rein Therapeutics Receives EMA Approval to Launch Phase 2 RENEW Trial of LTI-03 in Germany and Poland

EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trial Trial will evaluate LTI-03, a first-in...

October 13, 2025 | Monday | News
KARL STORZ Receives FDA Clearance for ENDOFLATOR™ +, the Next Generation in Surgical Insufflation and Smoke Evacuation

KARL STORZ, a global leader in minimally invasive surgical technology, is proud to announce it has received U.S. Food and Drug Administration (FDA) clear...

October 06, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close